CTCBIO Past Earnings Performance
Past criteria checks 0/6
CTCBIO has been growing earnings at an average annual rate of 17.6%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 2% per year.
Key information
17.6%
Earnings growth rate
24.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 2.0% |
| Return on equity | -20.4% |
| Net Margin | -12.0% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How CTCBIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 134,346 | -16,154 | 46,873 | 3,201 |
| 31 Mar 24 | 135,825 | -14,161 | 45,053 | 3,177 |
| 31 Dec 23 | 137,878 | -15,588 | 42,861 | 2,639 |
| 30 Sep 23 | 138,214 | -8,999 | 42,078 | 2,264 |
| 30 Jun 23 | 145,562 | -6,554 | 41,629 | 2,216 |
| 31 Mar 23 | 150,208 | -3,758 | 40,546 | 2,240 |
| 31 Dec 22 | 165,206 | 4,704 | 38,841 | 2,414 |
| 30 Sep 22 | 172,996 | 10,072 | 36,228 | 2,932 |
| 30 Jun 22 | 167,235 | 3,990 | 35,071 | 3,171 |
| 31 Mar 22 | 157,384 | -2,345 | 33,422 | 3,330 |
| 31 Dec 21 | 140,318 | -7,318 | 31,421 | 3,090 |
| 30 Sep 21 | 130,017 | -8,843 | 30,064 | 3,951 |
| 30 Jun 21 | 130,642 | -4,376 | 28,113 | 3,752 |
| 31 Mar 21 | 132,378 | -17,045 | 27,031 | 3,865 |
| 31 Dec 20 | 130,032 | -19,458 | 27,000 | 3,907 |
| 30 Sep 20 | 135,117 | -20,733 | 26,665 | 2,894 |
| 30 Jun 20 | 135,041 | -23,733 | 26,276 | 2,370 |
| 31 Mar 20 | 136,645 | -13,006 | 27,643 | 2,155 |
| 31 Dec 19 | 136,124 | -13,739 | 25,989 | 2,404 |
| 30 Sep 19 | 134,619 | -15,681 | 30,550 | 2,976 |
| 30 Jun 19 | 133,567 | -13,948 | 32,400 | 3,843 |
| 31 Mar 19 | 132,269 | -10,440 | 32,396 | 4,227 |
| 31 Dec 18 | 138,400 | -9,061 | 35,278 | 4,584 |
| 30 Sep 18 | 136,755 | -18,318 | 35,532 | 4,277 |
| 30 Jun 18 | 136,358 | -20,435 | 35,105 | 6,056 |
| 31 Mar 18 | 135,374 | -18,933 | 34,986 | 5,768 |
| 31 Dec 17 | 130,559 | -20,698 | 35,468 | 5,777 |
| 30 Sep 17 | 127,007 | -10,679 | 30,668 | 7,578 |
| 30 Jun 17 | 129,176 | -5,383 | 29,185 | 7,446 |
| 31 Mar 17 | 126,689 | -4,713 | 27,805 | 7,694 |
| 31 Dec 16 | 123,146 | -2,739 | 25,619 | 7,365 |
| 30 Sep 16 | 124,483 | 3,796 | 25,685 | 5,708 |
| 30 Jun 16 | 116,796 | 645 | 25,438 | 4,127 |
| 31 Mar 16 | 115,296 | 1,158 | 25,173 | 4,291 |
| 31 Dec 15 | 118,991 | 2,740 | 26,315 | 4,930 |
| 30 Sep 15 | 118,321 | 559 | 27,735 | 5,360 |
| 30 Jun 15 | 120,961 | 2,711 | 28,371 | 5,574 |
| 31 Mar 15 | 123,169 | -1,439 | 28,964 | 6,094 |
| 31 Dec 14 | 121,855 | -3,502 | 28,672 | 5,952 |
| 30 Sep 14 | 122,697 | -5,188 | 27,255 | 5,837 |
| 30 Jun 14 | 125,847 | -3,608 | 26,825 | 4,871 |
| 31 Mar 14 | 124,541 | -719 | 26,593 | 4,187 |
| 31 Dec 13 | 123,387 | 935 | 25,625 | 4,088 |
| 30 Sep 13 | 123,459 | 1,141 | 26,432 | 3,727 |
Quality Earnings: A060590 is currently unprofitable.
Growing Profit Margin: A060590 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A060590 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.6% per year.
Accelerating Growth: Unable to compare A060590's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A060590 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).
Return on Equity
High ROE: A060590 has a negative Return on Equity (-20.41%), as it is currently unprofitable.